4D Molecular Therapeutics (NASDAQ:FDMT) Stock: Insider Scott Bizily Sells 1,635 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the stock in a transaction that occurred on Friday, October 16th. The shares were sold at an average price of $12.84, for a total value of $20,993.40. Following the transaction, the insider owned 8,617 shares in the company, valued at $110,642.28. This trade represents a 15.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Scott Bizily also recently made the following trade(s):

• On Wednesday, September 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $13.65, for a total transaction of $22,317.75.
• On Tuesday, September 1st, Scott Bizily sold 584 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $14.00, for a total transaction of $8,176.00.
• On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total transaction of $19,620.00.
• On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.20, for a total transaction of $19,947.00.

4D Molecular Therapeutics Stock Performance

FDMT opened at $12.62 on Thursday. The firm’s fifty day simple moving average is $14.07 and its two-hundred day simple moving average is $11.60. 4D Molecular Therapeutics, Inc. has a 52-week low of $6.96 and a 52-week high of $16.93. The company has a market cap of $697.13 million, a price-to-earnings ratio of -4.80 and a beta of 2.75. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. The company had revenue of $3.78 million for the quarter, compared to analysts’ expectations of $3.62 million. Equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds have recently modified their holdings of the business. Toth Financial Advisory Corp purchased a new stake in 4D Molecular Therapeutics during the 3rd quarter valued at about $29,000. Opaleye Management Inc. raised its holdings in 4D Molecular Therapeutics by 197.8% in the 2nd quarter. Opaleye Management Inc. now owns 334,437 shares of the company’s stock valued at $4,448,000 after acquiring an additional 222,146 shares during the last quarter. Engineers Gate Manager LP raised its holdings in 4D Molecular Therapeutics by 132.0% in the 2nd quarter. Engineers Gate Manager LP now owns 68,206 shares of the company’s stock valued at $907,000 after acquiring an additional 38,806 shares during the last quarter. AXQ Capital LP acquired a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at about $186,000. Finally, Headlands Technologies LLC lifted its stake in 4D Molecular Therapeutics by 20.6% in the 2nd quarter. Headlands Technologies LLC now owns 19,238 shares of the company’s stock worth $256,000 after purchasing an additional 3,282 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

FDMT has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Thursday, October 15th. Bank of America raised their target price on 4D Molecular Therapeutics from $29.00 to $33.00 and gave the company a “buy” rating in a research report on Tuesday, September 29th. The Goldman Sachs Group restated a “buy” rating and issued a $32.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. Cantor Fitzgerald raised 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price target on the stock in a research note on Monday, September 14th. Finally, B. Riley Financial reiterated a “buy” rating on shares of 4D Molecular Therapeutics in a research report on Monday, August 17th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $28.90.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to design adeno-associated virus (AAV) vectors intended to deliver genetic medicines to specific tissues and organs.

Its pipeline has focused primarily on ophthalmology and pulmonology. Key investigational programs have included 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema, and 4D-710, an inhaled gene therapy designed to address the underlying cause of cystic fibrosis in patients who cannot benefit from existing CFTR modulator treatments.